Please refer to the Background Document for an elaboration of these concepts. RfDs can also be derived for the noncarcinogenic health effects of substances that are also carcinogens. Therefore, it is essential to refer to other sources of information concerning the carcinogenicity of this substance. If the U.S. EPA has evaluated this substance for potential human carcinogenicity, a summary of that evaluation will be contained in Section II of this file. Ninety-day subchronic toxicity test with sodium azide in Fischer 344 rats.
Data regarding the effects of oral exposure of humans to sodium azide are available, but limited.
In a separate study, Black et al. No evidence of damage to the kidney, heart or liver was detected in routine clinical studies of the three hypertensive patients who ingested sodium azide for 1-2.5 years. Sodium azide is a metabolic inhibitor that interferes with oxidative enzymes and inhibits phosphorylation. Medium confidence in the RfD follows. This assessment is not presented in any existing U.S. EPA document.